Stem Cell Clinic

10 things to know about stem cell therapy – Outlook India

10 things to know about stem cell therapy

New Delhi, March 3 (IANSlife) The usage of stem cells to cure or treat a disease or repair the injured tissue is defined as stem cell therapy. The best example of the stem cell treatment is seen in patients suffering from restoring the vision of the damaged eyes, grafting of the skin in severe burnt conditions. Stem cell treatments for brain or neural diseases like Parkinson''s and Alzheimer''s disease, multiple sclerosis, preventing heart strokes, curing diabetes, kidney disorders, autism, and spinal cord injuries are progressively making their way. Vipul Jain, CEO of Advancells and also a Serial entrepreneur, explains in detail the treatment, its uses, cost and effectiveness.

Q: What are stem cells?

Undifferentiated cells that are able to differentiate and transform into any type of cells of the body when and where needed. They have an enormous potential to repair, heal and regenerate. Stem cells come from blood, bone marrow, umbilical cord blood and adipose tissue.

Types of stem cell therapy

Autologous stem cell therapy: Patient receives stem cells from his/her own body

Allogeneic stem cell therapy: Patient receives the stem cells donated by another individual

Autologous stem cell therapy is better than allogeneic stem cell therapy as chances of mismatching are not there and they pose the minimum risk of immune rejection. Also, no side effects or adverse effects are seen as a person''s own blood cells are used. They start the healing process immediately in a natural way.

What is stem cell therapy?

The usage of stem cells to cure or treat a disease or repair the injured tissue is defined as stem cell therapy. Stem cells can be obtained from the bone marrow, adipose tissues etc. Due to their tremendous potential to prevent and to treat various health conditions and to repair the injured tissues global research investigation is continuously being done as to explore the maximum advantage of these cell lines.

The best example of the stem cell treatment is seen in patients suffering from restoring the vision of the damaged eyes, grafting of the skin in severe burnt conditions. Stem cell treatments for brain or neural diseases like Parkinson''s and Alzheimer''s disease, multiple sclerosis, preventing heart strokes, curing diabetes, kidney disorders, autism, and spinal cord injuries are progressively making their way.

What are the sources of stem cell?

Depending upon the disease, different stem cell source can be used in a specific condition. The procedure may involve the extraction of stem cells from adipose tissue-derived stem cells with the combination of PRP (Platelet-rich plasma) or can be obtained from bone marrow that can differentiate into progenitor cells that differentiate into various other tissues which can help in the therapy.

Procedure of stem cell therapy

The stem cells are isolated from the bone marrow or adipose tissues followed by their processing and enrichment under sterile conditions. These activated stem cells are placed back into the patient''s body at the target site for repairing the damaged tissue. It is necessary that the stem cells are injected in the specific area of injury as only then the desired results will be achieved.

Adipose stem cells are preferred over bone marrow stem cells as they are easy to isolate and contain a higher number of stem cells.

Stem cells injection

The stem cells injections are gaining much interest because it is devoid of the painful procedure, takes less time in comparison to a surgery, there are no host and recipient rejections as stem cells are harvested from the patient''s body itself and a targeted delivery system is available.

The stem cells obtained are processed in a sophisticated stem cell lab and after activation are inserted back into the host with the help of intravenous, intramuscular, intra-arterial, intradermal and intrathecal injections as per the requirement of the treatment process.

What is the use of anesthetics and why? Usually, local anesthetics are used during a stem cell procedure to numb the area but sometimes general anesthesia is also given while extracting the stem cells from bone marrow. But it is necessary to find out what anesthetic your doctor uses during orthopedic stem cell treatments.

A number of anesthetics have been found to kill the stem cells thus; the treatment''s end result will greatly depend on the use of anesthetics. Some anesthetics very well sync with the stem cell and hence, aid in the treatment.

How good are the processing techniques in the onsite labs?

Stem cells are to be extracted and processed in a clean room, under aseptic conditions maintaining a controlled environment. The doctor should explain the entire process and the number of viable stem cells infused into the patient during the process. Also, the precision of the injections to provide good quality of stem cells at the site of injury will help in better and faster recovery of the patient''s damaged area.

Duration and cost of the therapy

Cost of the treatment and its duration varies from one patient to another. The disease which needs to be cured, the severity, age factor, health condition, etc, define the duration of the therapy. One may respond during the treatment phase itself while the other may show results after a few sessions or weeks. Depending upon the disease diagnosed, the stem cells extracted, duration of the therapy, other adjuvants used in the process, the cost of the stem cell therapy can vary.

Follow-up visits

It is essential that after the stem cell therapy the patient should visit the stem cell doctor for recuperation therapies. The primary goals of such therapy is the prevention of secondary complications, analysis of recovery of motor, sensory and all the bodily functioning, psychological support/counseling for depression, mood swings or anxiety etc. and reintegration into the community.

There can be different sets of precautions which need to be followed at various steps for the recovery of the damaged tissues. The treatment and post treatment conditions may vary from person to person depending upon the disease and the severity.

Success rate of stem cell therapy

Stem cell therapy has shown results in treating serious ailments like leukemia, grafting tissues, autism, orthopedic conditions and skin problems etc. Stem Cell Therapy has been successfully used in the treatment of around 80 serious disorders.

Survival rates among patients who received stem cell treatment are significantly high, whether the cell donors are related or unrelated to them. With the ongoing research around the world, scientists are exploring new possibilities in which a number of life threatening diseases can be prevented and cured hence, the stem cells have proved to be promising in the near future as many aspects are yet to be revealed.

--IANS

pg/adr/

Disclaimer :- This story has not been edited by Outlook staff and is auto-generated from news agency feeds. Source: IANS

Here is the original post:
10 things to know about stem cell therapy - Outlook India

Global Research Antibodies Market Expected to Grow with a CAGR of 6.2% During the Forecast Period, 2020-2027 – ResearchAndMarkets.com – Yahoo Finance

The "Research Antibodies Market Size, Share & Trends Analysis Report by Type (Monoclonal, Polyclonal), by End Use, by Product, by Technology, by Source, by Application (Oncology, Stem Cells), and Segment Forecasts, 2020 - 2027" report has been added to ResearchAndMarkets.com's offering.

The global research antibodies market size is expected to reach USD 5.6 billion by 2027, exhibiting a CAGR of 6.2% over the forecast period according to this report.

Major market drivers include rise in R&D initiatives undertaken by biopharmaceutical and biotechnology companies and government bodies, growing interest in the study of neurobiology and stem cell, availability of technologically advanced products, and strategic collaborations among various market players and academic research organizations.

Designer antibodies are also anticipated to attract the attention of various academic organizations for their use in the R&D of novel products. For instance, in April 2019, scientists from ALS Canada Research Program developed a set of antibodies that can help in the detection of misfolded TDP-43 in various lab experiments that utilize post-mortem brain tissues. Rising usage of research antibodies for the development of novel diagnostic therapies is thus anticipated to fuel market growth in the near future.

Increase in the usage of research antibodies to develop treatment options for various diseases is also expected to boost market growth during the forecast period. For instance, in June 2019, the Institute of Life Sciences (ILS, India) developed antibodies against chikungunya viral infection. These antibody structures were developed to aid in the understanding of various aspects of virus pathogenesis, entailing further research on antiviral therapies. Growing government funds and initiatives for R&D is anticipated to fuel the Asia Pacific market during the forecast period. According to the 2018-2019 Australian Budget, approximately USD 94 million was estimated for four years for new industry collaborations, research as well as new biomedical and medical programs.

Additionally, rise in funds invested by pharmaceutical and biotechnology companies to enhance the study of proteomics and genomics is expected to drive the market. For instance, in 2017, Biognosys Inc. raised USD 5 million in funds to increase, advance, and develop next-generation proteomics products and workflow for high throughput and high content protein analysis. Rise in the number of major market players investing in advanced technologies and collaborating with other market players is also anticipated to positively impact market potential in the near future. For instance, Abcellera uses technologically advanced techniques to test antibodies from single B cells, map and screen natural immune responses, and to discover novel antibody therapies. The company has also partnered with Sanofi, Pfizer, Teva, Merck, and GSK to discover and develop new antibody-based therapies.

North America dominated the research antibodies market in owing to increasing focus on R&D in the fields of biomedicine, stem cell, and cancer. Rising prevalence of chronic diseases such as cardiovascular and blood diseases is also expected to fuel market growth.

Further key findings from the report suggest:

Key Topics Covered:

Chapter 1 Methodology and Scope

1.1 Market segmentation & scope

1.2 Market definition

1.3 Information procurement

1.4 Information analysis

1.5 Market formulation & data visualization

1.6 Data validation & publishing

Chapter 2 Executive Summary

2.1 Market Outlook

2.2 Segment Outlook

2.3 Competitive Insights

Chapter 3 Research Antibodies Market Variables, Trends & Scope

3.1 Market Lineage Outlook

3.2 Penetration And Growth Prospect Mapping

3.3 Regulatory Framework

3.4 Market Dynamics

3.5 Research Antibodies Market Analysis Tools

Chapter 4 Research Antibodies Market - Competitive Analysis

4.1 Recent Developments & Impact Analysis, By Key Market Participants

4.2 Company Categorization

4.3 Public Companies

4.4 Private Companies

Chapter 5 Research Antibodies Market: Product Estimates And Trend Analysis

5.1 Definition & Scope

5.2 Product Market Share Analysis, 2019 & 2027

5.3 Segment Dashboard

5.4 Global Research Antibodies Market, By Product, 2016 To 2027

Story continues

5.5 Market Size & Forecasts And Trend Analyses, 2016 To 2027

5.6 Primary Antibodies

5.7 Secondary Antibodies

Chapter 6 Research Antibodies Market: Type Estimates And Trend Analysis

6.1 Definition & Scope

6.2 Type Market Share Analysis, 2019 & 2027

6.3 Segment Dashboard

6.4 Global Research Antibodies Market, By Type, 2016 To 2027

6.5 Market Size & Forecasts And Trend Analyses, 2016 To 2027

6.6 Monoclonal Antibodies

6.7 Polyclonal Antibodies

Chapter 7 Research Antibodies Market: Technology Estimates And Trend Analysis

7.1 Definition & Scope

7.2 Technology Market Share Analysis, 2019 & 2027

7.3 Segment Dashboard

7.4 Global Research Antibodies Market, By Technology, 2016 To 2027

7.5 Market Size & Forecasts And Trend Analyses, 2016 To 2027

7.6 Immunochemistry

7.7 Immunofluorescence

7.8 Western Blotting

7.9 Flow Cytometry

7.10 Immunoprecipitation

7.11 Elisa

7.12 Other Technologies

Chapter 8 Research Antibodies Market: Application Estimates And Trend Analysis

8.1 Definition & Scope

8.2 Application Market Share Analysis, 2019 & 2027

8.3 Segment Dashboard

8.4 Global Research Antibodies Market, By Application, 2016 To 2027

8.5 Market Size & Forecasts And Trend Analyses, 2016 To 2027

8.6 Infectious Diseases

8.7 Immunology

8.8 Oncology

8.9 Stem Cells

8.10 Neurobiology

8.11 Other Applications

Chapter 9 Research Antibodies Market: Source Estimates And Trend Analysis

9.1 Definition & Scope

9.2 Source Market Share Analysis, 2019 & 2027

9.3 Segment Dashboard

9.4 Global Research Antibodies Market, By Source, 2016 To 2027

9.5 Market Size & Forecasts And Trend Analyses, 2016 To 2027

9.6 Mouse Antibodies

9.7 Rabbit Antibodies

9.8 Goat Antibodies

9.9 Other Sources

Chapter 10 Research Antibodies Market: End Use Estimates And Trend Analysis

10.1 Definition & Scope

10.2 End Use Market Share Analysis, 2019 & 2027

10.3 Segment Dashboard

10.4 Global Research Antibodies Market, By End Use, 2016 To 2027

10.5 Market Size & Forecasts And Trend Analyses, 2016 To 2027

10.6 Academic & Research Institutes

10.7 Contract Research Organizations

10.8 Pharmaceutical & Biotechnology Companies

Chapter 11 Research Antibodies Market: Regional Estimates & Trend Analysis

11.1 Regional Market Snapshot

11.2 Market Share Analysis By Country, 2019

11.3 SWOT Analysis, By Factor

11.4 Market Size & Forecasts, And Trend Analysis, 2019 To 2026

11.4.1 North America

11.4.2 Europe

11.4.3 Asia Pacific

Original post:
Global Research Antibodies Market Expected to Grow with a CAGR of 6.2% During the Forecast Period, 2020-2027 - ResearchAndMarkets.com - Yahoo Finance

aTyr Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting – BioSpace

SAN DIEGO, March 03, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma Inc., (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the company will present an abstract in a poster session at the upcoming AACR Annual Meeting, which is being held April 24 29, 2020 at the San Diego Convention Center.

Details of the presentation are as follows:Title:Domain-specific antibodies to Neuropilin-2 implicate VEGF-C and not Semaphorin 3F in breast cancer stem cell functionSession Date and Time:Monday, Apr 27, 2020 9:00 AM - 12:30 PMAbstract Control Number:7308Session Category:Experimental and Molecular TherapeuticsSession Title:Identification of Molecular Targets 1Location: San Diego Convention Center, Exhibit Halls A-F, Poster Section 25Poster Board Number:14Permanent Abstract Number: 1785

About ATYR1923

aTyr is developing ATYR1923 as a potential therapeutic for patients with interstitial lung diseases. ATYR1923, a fusion protein comprised of the immuno-modulatory domain of histidyl tRNA synthetase fused to the FC region of a human antibody, is a selective modulator of neuropilin-2 that downregulates the innate and adaptive immune response in inflammatory disease states. aTyr is currently enrolling a proof-of-concept Phase 1b/2a trial evaluating ATYR1923 in patients with pulmonary sarcoidosis. This Phase 1b/2a study is a multi-ascending dose, placebo-controlled, first-in-patient study of ATYR1923 that has been designed to evaluate the safety, tolerability, steroid sparing effect, immunogenicity and pharmacokinetics profile of multiple doses of ATYR1923.

About aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. aTyrs research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyrs primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases. For more information, please visit http://www.atyrpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act. Forward-looking statements are usually identified by the use of words such as anticipates, believes, estimates, expects, intends, may, plans, projects, seeks, should, will, and variations of such words or similar expressions. We intend these forward-looking statements to be covered by such safe harbor provisions for forward-looking statements and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, include statements regarding the potential therapeutic benefits and applications of our product candidates; our ability to successfully advance our product candidates, undertake certain development activities (such as the initiation of clinical trials, clinical trial enrollment, the conduct of clinical trials and the announcement of top-line results) and accomplish certain development goals, and the timing of such events; and the scope and strength of our intellectual property portfolio. These forward-looking statements also reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects, as reflected in or suggested by these forward-looking statements, are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. Furthermore, actual results may differ materially from those described in these forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks associated with the discovery, development and regulation of our product candidates, the risk that we may cease or delay preclinical or clinical development activities for any of our existing or future product candidates for a variety of reasons (including difficulties or delays in patient enrollment in planned clinical trials), the possibility of unexpected expenses or other demands on our cash resources, and the risk that we may not be able to raise the additional funding required for our business and product development plans, as well as those risks set forth in our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and in our other SEC filings. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

More here:
aTyr Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting - BioSpace

The Global Cell Viability Assays MARKET is expected to grow by USD 1.40 bn during 2020-2024, progressing at a CAGR of 8% during the forecast period -…

Global Cell Viability Assays Market 2020-2024 The analyst has been monitoring the global cell viability assays market and it is poised to grow by USD 1. 40 bn during 2020-2024, progressing at a CAGR of 8% during the forecast period.

New York, March 02, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Cell Viability Assays Market 2020-2024" - https://www.reportlinker.com/p05868124/?utm_source=GNW Our reports on global cell viability assays market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by growing emphasis on timely diagnosis of diseases.In addition, growing focus on stem cell research is anticipated to boost the growth of the global cell viability assays market as well.

Market Segmentation The global cell viability assays market is segmented as below: Product: o Consumables

o Instruments

Geographic Segmentation: o North America

o APAC

o Europe

o South America

o MEA

Key Trends for global cell viability assays market growth This study identifies growing focus on stem cell research as the prime reasons driving the global cell viability assays market growth during the next few years.

Prominent vendors in global cell viability assays market We provide a detailed analysis of around 25 vendors operating in the global cell viability assays market, including some of the vendors such as Agilent Technologies Inc., Becton, Dickinson and Co., Bio-Rad Laboratories Inc., Biotium Inc., Danaher Corp., General Electric Co., Merck KGaA, PerkinElmer Inc., Promega Corp. and Thermo Fisher Scientific Inc. . The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.Read the full report: https://www.reportlinker.com/p05868124/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Read the original here:
The Global Cell Viability Assays MARKET is expected to grow by USD 1.40 bn during 2020-2024, progressing at a CAGR of 8% during the forecast period -...

BioIVT Now Provides Same-day Delivery of Fresh Leukopaks and Immune Cell Products in the UK and Over – PharmiWeb.com

WESTBURY, N.Y., March 3, 2020 /PRNewswire/ --BioIVT, a leading provider of research models and services for drug and diagnostic development, announced that it is now providing same-day delivery of fresh blood, LEUKOMAX leukopaks and buffy coats from normal and disease-state donors to cell and gene therapy researchers in the UK. BioIVT is also shipping these products overnight to certain EU locations.

This service is being offered through BioIVT's CTLS donor center in London, which sees more than 2,500 donors per year. Since BioIVT acquired CTLS in 2018, it has expanded CTLS' capabilities by introducing Spectra Optia apheresis systems, which allow it to collect leukopaks on site. BioIVT is now a premier provider of fresh leukopaks to the EU community.

"BioIVT is continuing to grow its business strategically to meet the exact needs of our clients. We currently have six donor centers located in California, Tennessee, Pennsylvania, and London. The placement of our sites allows us to provide cell and gene therapy researchers across the US, UK and Europe with viable solutions precisely when they need them," said BioIVT CEO Jeff Gatz.

"The UK is a hub for cell therapy, gene therapy and pharmaceutical companies who all require access to fresh blood and blood-derived immune cells for their research," said BioIVT General Manager of EU Operations Kelly Sapsford. "As speed is of the essence for many of these clients, we have improved the efficiency with which we produce our high-quality blood products to allow same-day delivery."

Leukopaks contain concentrated white blood cells and are used to help identify promising new drug candidates, assess toxicity levels, and conduct stem cell and gene therapy research. They are useful for researchers who need to obtain large numbers of leukocytes from a single donor.

BioIVT can also provide isolated peripheral blood mononuclear cells (PBMCs) from its leukopaks to meet specific donor and specimen parameters. Both leukopaks and isolated PBMCs can be provided from repeat donors and those that have been human leukocyte antigen (HLA), FC receptor or cytomegalovirus typed. HLA typing is used to match patients and donors for bone marrow or cord blood transplants. FC receptors plays an important role in antibody-dependent immune responses.

Donors can be recruited based on specific criteria, such as body mass index, smoking status, age, gender, ethnicity and in some cases medications taken. All BioIVT donors are consented under institutional review board (IRB-) approved protocols and its staff follows European Medicines Agency (EMA) standards and American Association of Blood Banks (AABB) guidelines.

Further information about BioIVT's new UK-based product lines is available at https://hubs.ly/H0ngR8G0.

About BioIVTBioIVT is a leading global provider of research models and value-added research services for drug discovery and development. We specialize in control and disease-state biospecimens including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. Our PHASEZERO Research Services team works collaboratively with clients to provide target and biomarker validation, phenotypic assays to characterize novel therapeutics, clinical assay development and in vitro hepatic modeling solutions. And as the premier supplier of hepatic products, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly-discovered compounds and their effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in elevating science. For more information, please visit http://www.bioivt.com or follow the company on Twitter @BioIVT.

BioIVT Contact: Courtney Noah, SVP, Marketing & Client Services, 516-483-1196Media Contact: Lisa Osborne, Rana Healthcare Solutions, 206-992-5245, lisa@ranahealth.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/bioivt-now-provides-same-day-delivery-of-fresh-leukopaks-and-immune-cell-products-in-the-uk-and-overnight-to-eu-locations-301014818.html

SOURCE BioIVT

Read the original here:
BioIVT Now Provides Same-day Delivery of Fresh Leukopaks and Immune Cell Products in the UK and Over - PharmiWeb.com

$6.36 Billion Flow Cytometry Market by Product & Solution, Technology, Application, End-user and Region – Forecast to 2027 -…

DUBLIN--(BUSINESS WIRE)--The "Flow Cytometry Market by Product and Solution (Consumables, Instrument, Software, Service), Technology (Cell-based, Bead-based), Application (Cancer, Immunology, Hematology), and End-user (Pharmaceutical, Biotech, Academia) - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

The global flow cytometry market is expected to grow at a CAGR of 8.2% from 2019 to 2027 to reach $6.36 billion by 2027.

The growth in the overall flow cytometry market is mainly attributed to rising global incidence and prevalence of chronic diseases, increasing adoption of flow cytometry techniques in research and academia, and growing initiatives in the field of immunology and immuno-oncology researches. In addition, evolving pipeline for stem cell research and adoption of recombinant DNA technology for antibody production will further provide significant opportunities for the various stakeholders in this market.

The overall flow cytometry market is mainly segmented by product and solution (instruments, software, accessories, services), technology (cell-based flow cytometry, bead-based flow cytometry), application (research, clinical, and industrial), end-user (research and academic institutes, diagnostic laboratories, pharmaceutical & biotechnology companies), and geography.

On the basis of technology, bead-based technology segment is expected to grow at the highest CAGR during the forecast period. Procedural advantages offered by this technology over other cell-based technologies (such as ELISA and western blot), including its capacity to detect multiple analytes, high reproducibility, stability, and speed are expected to propel its growth.

On the basis of product and solution, the consumables and reagents segment accounted for the largest share of the overall flow cytometry market in 2019. Frequent utilization of application-specific reagents and assays by the end users is supporting the growth of this segment.

On the basis of application area, drug discovery segment held the largest share of the overall flow cytometry market in 2019. A wide variety of flow cytometry methods with the implementation of multi-parameter intracellular flow cytometric analysis have been employed at different stages of drug discovery and development. The growing demand for such advanced technologies used during drug discovery processes to simplify complicated cell analysis procedures is expected to drive the growth of this segment.

Based on end user, the pharmaceutical and biotechnology companies segment accounted for the largest share of this market in 2019. Increasing chronic cases leading to the development of new drugs and rise in R&D expenditure by companies is contributing to the growth of this segment.

An in-depth analysis of the geographical scenario of the flow cytometry market provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. North America commanded the largest share of the global flow cytometry market in 2019, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

The key players operating in the global flow cytometry market are Agilent Technologies, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Apogee Flow Systems Ltd. (U.K.), Sysmex Partec GmbH (Germany), Luminex Corporation (U.S.), Miltenyi Biotec GmbH (Germany), Bio-Rad Laboratories, Inc. (U.S.), bioMerieux S.A. (France), Cytonome/ST LLC (U.S.), Beckman Coulter, Inc. (U.S.), and Becton, Dickinson and Company (U.S.) among others.

Market Dynamics

Drivers

Restraint

Opportunities

Challenges

Scope of the Report

Global Flow Cytometry Market, by Technology

Global Flow Cytometry Market, by Product & Services

Global Flow Cytometry Market, by Application

Global Flow Cytometry Market, by End User

Global Flow Cytometry Market, by Geography

Company Profiles

(Business Overview, Financial Overview, Product Portfolio, Strategic Developments)

For more information about this report visit https://www.researchandmarkets.com/r/16q5f

Continued here:
$6.36 Billion Flow Cytometry Market by Product & Solution, Technology, Application, End-user and Region - Forecast to 2027 -...

Human Embryonic Stem Cell (hESC) Market 2020 By Top Key Players/Manufacturers, Type and Application, Regions, Industry Analysis, Growth, Size, Trends,…

Global Human Embryonic Stem Cell (hESC) Market Overview:

The global Human Embryonic Stem Cell (hESC) Market is comprehensively analyzed in the report with a huge focus on industry dynamics, competitive landscape, regional and country-level analysis, segmental analysis, and major growth strategies. The market size in terms of both revenue and volume has been included in the report for the period 2015-2026. Moreover, the report provides qualitative business environment information which has been formulated by using tools such as PESTEL analysis, Porters Five Forces, and SWOT analysis.

The global Human Embryonic Stem Cell (hESC) Market accounted for a market size of $XXX million in 2019 and is anticipated to register a CAGR of XX% over the forecast period.

Download Free Sample Report Copy of Human Embryonic Stem Cell (hESC) Market Now @ http://researchindustry.us/report/human-embryonic-stem-cell-hesc-market-rie/788874/request-sample

Market Segmentation:

The global Human Embryonic Stem Cell (hESC) Market is segmented on the basis of segment 1, segment 2, segment 3, and segment 4. The report includes detailed information on all market segments and sub-segments and the factors impacting the market growth. In addition, the report consists of the market size of all the segments and sub-segments for historical and the forecast period along with compound annual growth rate (CAGR).

The global Human Embryonic Stem Cell (hESC) Market has been segmented into:

By Type:

Totipotent Stem CellPluripotent Stem CellUnipotent Stem Cell

By Application:

ResearchClinical TrialsOthers

Request Table of Content and Figures @ http://researchindustry.us/report/human-embryonic-stem-cell-hesc-market-rie/788874/toc

Regional Analysis

On regional and country-level, the market has been segmented as follows:

The report includes an in-depth assessment of all market segments in each region and country in the study scope. In addition, the study includes the market size for all regions and countries from the year 2015 to 2026. Macro-economic and micro-economic factors influencing the market growth in each region has been studied comprehensively in the report. Further, the report consist of recent market developments in each country.

Competitive Landscape:

The study involves company profiles of various key companies operating in the global Human Embryonic Stem Cell (hESC) Market. The financial outlooks of these companies, their research and development statuses, product offering, and their development strategies for the coming years are provided in the report. In addition, the report consists of a comprehensive list of the strategic initiatives undertaken by prominent companies in recent years to obtain a competitive edge in the market.

Prominent Companies in the global Human Embryonic Stem Cell (hESC) Market:

Astellas Institute of Regenerative Medicine (US)Asterias Biotherapeutics, Inc. (US)BD Biosciences (US)Cell Cure Neurosciences Ltd. (Israel)Cellular Dynamics International (US)GE Healthcare (UK)MilliporeSigma (US)PerkinElmer, Inc. (US)Reliance Life Sciences Ltd. (India)Research & Diagnostics Systems, Inc. (US)SABiosciences Corp. (US)STEMCELL Technologies, Inc. (Canada)Stemina Biomarker Discovery, Inc. (US)Takara Bio, Inc. (Japan)TATAA Biocenter AB (Sweden)Thermo Fisher Scientific, Inc. (US)UK Stem Cell Bank (UK)ViaCyte, Inc. (US)Vitrolife AB (Sweden)

You Can Directly Buy This Report from Here (Get Instant Discount $1000) @ http://researchindustry.us/checkout?report=788874&type=single

Research Methodology:

The research methodology adopted for formulating the global Human Embryonic Stem Cell (hESC) Market report is based on detailed primary and secondary research. For primary research, interviews were conducted with key opinion leaders such as market stakeholders, investors, brand managers, vice presidents, sales managers, and marketing managers. Based on data obtained from primary respondents, the changing scenario of the global Human Embryonic Stem Cell (hESC) Market was emphasized. Further, for secondary research, various public and paid databases were utilized along with annual report publications, white papers, and key players press releases to obtain the required data for analysis. Moreover, a mixture of bottom-up and top-down approaches were utilized for market engineering process.

Reasons to Purchase Global Human Embryonic Stem Cell (hESC) Report

Request Customization or Discount of This Report @ http://researchindustry.us/report/human-embryonic-stem-cell-hesc-market-rie/788874/request-customization

Pointers Covered in TOC:

Chapter 1: This chapter includes executive summary, market definition and market scope.

Chapter 2:This chapter includes in-depth research methodology, information procurement, data analysis, assumptions & exclusions, and secondary data resources.

Chapter 3: This chapter consists of market trends, drivers, restraints, opportunities, business environment analysis tools, and market share analysis.

Chapter 4, 5, 6:These chapters consist of information of all market segments including market size and forecast (2019-2026).

Chapter 7: This chapter includes regional and country level analysis of global Human Embryonic Stem Cell (hESC) Market.

Chapter 8: This chapter includes company profiles of key market players

Chapter 9: List of Tables

Chapter 10: List of Figures

Research Industry US is a market research and consultative company that provides market research reports and business insights to large and small & medium enterprises. The company supports its clients to conceive business policies and accomplish sustainable growth in their particular market domain. We meet clients objectives, commitment and dedication on high standard and targeting possible prospects for market research reports. We value how imperative surveying statistical information is for your business or association. As a result, we are linked with the top publishers & research firms all dedicated in specific domains, ensuring you will receive the most consistent and up to date research data available.

Get In Touch!Research Industry USNavale ICON IT Park,Office No. 407, Mumbai Bangalore Highway, Narhe, PuneUSA:+1-213-275-4706IND+91-844-601-6060Email:[emailprotected]

Link:
Human Embryonic Stem Cell (hESC) Market 2020 By Top Key Players/Manufacturers, Type and Application, Regions, Industry Analysis, Growth, Size, Trends,...